Autoimmune Disease Diagnostics Market Companies Analysis, Size, Share, and Forecast
According to Renub Research Global Autoimmune Disease Diagnostics Market is poised for exceptional growth, projected to expand from US$ 5.70 billion in 2024 to US$ 10.63 billion by 2033, registering a robust CAGR of 7.17% between 2025 and 2033. Rising prevalence of autoimmune disorders, increasing awareness about early detection, advancements in diagnostic technologies, and growing emphasis on precision medicine are key factors driving market growth.
Autoimmune disorders occur when the body’s immune system mistakenly attacks healthy tissues, leading to conditions such as lupus, rheumatoid arthritis, multiple sclerosis, celiac disease, type 1 diabetes, and autoimmune thyroid diseases. Due to complex and overlapping symptoms, timely and accurate diagnosis becomes critical. Diagnostic evaluation typically involves patient history assessment, physical examination, and laboratory testing to detect autoantibodies and inflammatory markers.
Common diagnostic tools include Antinuclear Antibody (ANA) testing, Rheumatoid Factor (RF) testing, ENA profile, immunoassays, genetic testing, molecular diagnostics, and advanced imaging technologies. Improved diagnostic accuracy not only supports better treatment planning but also enhances long-term patient outcomes.
Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=autoimmune-disease-diagnostics-market-competitive-landscape-p.php
Advancements Transforming Autoimmune Disease Diagnostics
Technological innovation is reshaping the autoimmune diagnostics landscape. Automation, artificial intelligence, point-of-care testing, and improved assay sensitivity enable faster, more reliable results. Digitalization and integration of diagnostic platforms support streamlined workflows in hospitals, reference laboratories, and clinical diagnostic centers.
Strategic alliances between diagnostics companies and biotechnology firms are accelerating R&D in biomarker discovery, novel assay development, and high-throughput diagnostic technologies. Expansion of reimbursement coverage and growing investment in healthcare infrastructure further support market development.
Leading Companies in the Autoimmune Disease Diagnostics Market
The market is highly competitive, dominated by multinational diagnostic technology providers, biotechnology innovators, laboratory service leaders, and research-driven healthcare corporations. Below is an overview of major contributors shaping the market.
Abbott Laboratories
Founded in 1888 and headquartered in the United States, Abbott is a leading global healthcare and medical device company offering diverse diagnostics solutions including laboratory systems, rapid testing kits, molecular diagnostic tools, and immunoassays. Abbott’s strong international distribution network strengthens its presence across North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa.
Bio-Rad Laboratories
Founded in 1952 in the United States, Bio-Rad designs and manufactures high-precision instruments, consumables, and reagents for life science research and clinical diagnostics. Its autoimmune diagnostic kits, molecular diagnostics platforms, and blood typing solutions are widely used in hospitals, public health laboratories, and biotechnology facilities worldwide.
Roche Diagnostics
Headquartered in Switzerland, Roche Diagnostics develops advanced bioanalytical instruments, in-vitro diagnostic systems, molecular diagnostic tools, workflow solutions, and data-driven diagnostic software. Its strong innovation capability and global footprint make Roche a leading name in autoimmune disease diagnostics.
Siemens Healthineers
Siemens Healthineers, based in Germany, offers comprehensive diagnostic imaging, laboratory diagnostics, and healthcare IT solutions. Its powerful testing systems, molecular diagnostics, and digital health platforms support clinical laboratories and healthcare systems across regions including Europe, Americas, Middle East, Africa, and Asia-Pacific.
bioMérieux SA
France-based bioMérieux specializes in in-vitro diagnostics, developing systems, reagents, and software for infectious disease and autoimmune diagnostics. The company also supports industrial microbiological testing for pharmaceuticals, food, veterinary, and cosmetics industries.
Myriad Genetics
Myriad Genetics is a molecular diagnostics company focusing on genetic testing, personalized medicine, and precision diagnostics. Its autoimmune-related molecular testing portfolio supports early risk detection and treatment planning across major healthcare markets globally.
Key Market Developments
Quest Diagnostics
Quest Diagnostics is set to introduce the FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test in July 2025, marking a milestone in Alzheimer’s-related autoimmune diagnostic capability.
Thermo Fisher Scientific
In December 2023, Thermo Fisher signed an exclusive distribution agreement with Aesku.Group, enhancing its autoimmune diagnostics portfolio through expanded IFA testing and advanced automation technology.
Grifols
Grifols invested EUR 160 million in expanding plasma fractionation capacity, strengthening diagnostic and therapeutic capabilities across Europe.
Labcorp
In August 2025, Labcorp introduced Test Finder, an AI-powered platform developed with AWS to help clinicians select appropriate diagnostic tests using natural language queries.
Sustainability and ESG Leadership in the Diagnostics Market
Trinity Biotech Sustainability Commitment
Trinity Biotech focuses on eco-efficient manufacturing, waste reduction, ethical sourcing, and sustainable diagnostic innovation to minimize environmental footprint while enhancing global health outcomes.
Becton Dickinson (BD) Sustainability Strategy
BD’s “Together We Advance” ESG Strategy targets:
- 46% Scope 1 & 2 emissions reduction by 2030
- Carbon neutrality by 2040
- Reduction in energy, water, and waste
- Increased circular product design and reduced plastic dependency
These initiatives reinforce BD’s position as a responsible healthcare sustainability leader.
SWOT Insights – Key Industry Innovators
EUROIMMUN
Strength: Comprehensive autoimmune testing portfolio with 150+ specialized tests addressing over 80 autoimmune diseases. Strong clinical validation and guideline-aligned solutions support precision diagnosis and improved patient care.
Inova Diagnostics (Werfen)
Strength: Industry-leading autoimmune diagnostics portfolio providing broad disease coverage, high diagnostic accuracy, and strong clinical reliability supporting screening, diagnosis, and disease monitoring.
Market Research Scope and Analytical Framework
Comprehensive analysis of the Autoimmune Disease Diagnostics Market covers:
- Historical and forecast trends
- Market share evaluation
- Competitive benchmarking
- Company strategies & revenue analysis
- Mergers & acquisitions
- Partnerships and R&D investments
- Sustainability and ESG performance
- Product pipeline and innovation benchmarking
- SWOT assessments
Key Companies Covered in Market Analysis
Abbott Laboratories
Bio-Rad Laboratories
Roche Diagnostics
Siemens Healthineers
bioMérieux SA
Myriad Genetics
Quest Diagnostics
Thermo Fisher Scientific
EUROIMMUN
Inova Diagnostics (Werfen)
Grifols
LabCorp
Revvity
Trinity Biotech
BD (Becton Dickinson)
